Chlorin-Based Photoactivable Galectin-3-Inhibitor Nanoliposome for Enhanced Photodynamic Therapy and NK Cell-Related Immunity in Melanoma

Sijia Wang; Huifang Liu; Jing Xin; Ramtin Rahmanzadeh; Jing Wang; Cuiping Yao; Zhenxi Zhang

doi:10.1021/acsami.9b09560

Chlorin-Based Photoactivable Galectin-3-Inhibitor Nanoliposome for Enhanced Photodynamic Therapy and NK Cell-Related Immunity in Melanoma

Sijia Wang, Huifang Liu, Jing Xin, Ramtin Rahmanzadeh, Jing Wang, Cuiping Yao^*, Zhenxi Zhang

^*Corresponding author for this work

Institute of Biomedical Optics

Xi'an Jiaotong University

38 Citations (Scopus)

Abstract

Photodynamic therapy (PDT) is an encouraging alternative therapy for melanoma treatment and Ce6-mediated PDT has shown some exciting results in clinical trials. However, PDT in melanoma treatment is still hampered by some melanoma's protective mechanisms like antiapoptosis mechanisms and treatment escape pathways. Combined therapy and enhancing immune stimulation were proposed as effective strategies to overcome this resistance. In this paper, a Chlorin-based photoactivable Galectin-3-inhibitor nanoliposome (PGIL) was designed for enhanced Melanoma PDT and immune activation of Natural Killer (NK) cells. PGIL were synthesized by encapsulating the photosensitizer chlorin e6 and low molecular citrus pectin in the nanoliposome to realize NIR-triggered PDT and low molecular citrus pectin (LCP) release into the cytoplasm. The intracellular release of LCP inhibits the activity of galectin-3, which increases the apoptosis, inhibits the invade ability, and enhances the recognition ability of Natural Killer (NK) cells to tumor cells in melanoma cells after PDT. These effects of PGIL were tested in cells and nude mice, and the mechanisms during the in vivo treatment were preliminarily studied. The results showed that PGIL can be an effective prodrug for melanoma therapy.

Original language	English
Journal	ACS Applied Materials and Interfaces
Volume	11
Issue number	45
Pages (from-to)	41829-41841
Number of pages	13
ISSN	1944-8244
DOIs	https://doi.org/10.1021/acsami.9b09560
Publication status	Published - 13.11.2019

Funding

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. This work was supported by the National Natural Science Foundation of China under grant nos. 61705177, 61727823, 61875159, and 61775178, and by the China Postdoctoral Science Foundation under grant nos. 2018T111036 and 2017M613107. The authors declare no competing financial interest.

Research Areas and Centers

Academic Focus: Biomedical Engineering

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acsami.9b09560

Cite this

@article{fe7e097d0c664463859570230bce5bdd,

title = "Chlorin-Based Photoactivable Galectin-3-Inhibitor Nanoliposome for Enhanced Photodynamic Therapy and NK Cell-Related Immunity in Melanoma",

abstract = "Photodynamic therapy (PDT) is an encouraging alternative therapy for melanoma treatment and Ce6-mediated PDT has shown some exciting results in clinical trials. However, PDT in melanoma treatment is still hampered by some melanoma's protective mechanisms like antiapoptosis mechanisms and treatment escape pathways. Combined therapy and enhancing immune stimulation were proposed as effective strategies to overcome this resistance. In this paper, a Chlorin-based photoactivable Galectin-3-inhibitor nanoliposome (PGIL) was designed for enhanced Melanoma PDT and immune activation of Natural Killer (NK) cells. PGIL were synthesized by encapsulating the photosensitizer chlorin e6 and low molecular citrus pectin in the nanoliposome to realize NIR-triggered PDT and low molecular citrus pectin (LCP) release into the cytoplasm. The intracellular release of LCP inhibits the activity of galectin-3, which increases the apoptosis, inhibits the invade ability, and enhances the recognition ability of Natural Killer (NK) cells to tumor cells in melanoma cells after PDT. These effects of PGIL were tested in cells and nude mice, and the mechanisms during the in vivo treatment were preliminarily studied. The results showed that PGIL can be an effective prodrug for melanoma therapy.",

author = "Sijia Wang and Huifang Liu and Jing Xin and Ramtin Rahmanzadeh and Jing Wang and Cuiping Yao and Zhenxi Zhang",

note = "Funding Information: The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. This work was supported by the National Natural Science Foundation of China under grant nos. 61705177, 61727823, 61875159, and 61775178, and by the China Postdoctoral Science Foundation under grant nos. 2018T111036 and 2017M613107. The authors declare no competing financial interest. Publisher Copyright: Copyright {\textcopyright} 2019 American Chemical Society. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = nov,

day = "13",

doi = "10.1021/acsami.9b09560",

language = "English",

volume = "11",

pages = "41829--41841",

journal = "ACS Applied Materials and Interfaces",

issn = "1944-8244",

publisher = "American Chemical Society",

number = "45",

}

TY - JOUR

T1 - Chlorin-Based Photoactivable Galectin-3-Inhibitor Nanoliposome for Enhanced Photodynamic Therapy and NK Cell-Related Immunity in Melanoma

AU - Wang, Sijia

AU - Liu, Huifang

AU - Xin, Jing

AU - Rahmanzadeh, Ramtin

AU - Wang, Jing

AU - Yao, Cuiping

AU - Zhang, Zhenxi

N1 - Funding Information: The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. This work was supported by the National Natural Science Foundation of China under grant nos. 61705177, 61727823, 61875159, and 61775178, and by the China Postdoctoral Science Foundation under grant nos. 2018T111036 and 2017M613107. The authors declare no competing financial interest. Publisher Copyright: Copyright © 2019 American Chemical Society. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/11/13

Y1 - 2019/11/13

N2 - Photodynamic therapy (PDT) is an encouraging alternative therapy for melanoma treatment and Ce6-mediated PDT has shown some exciting results in clinical trials. However, PDT in melanoma treatment is still hampered by some melanoma's protective mechanisms like antiapoptosis mechanisms and treatment escape pathways. Combined therapy and enhancing immune stimulation were proposed as effective strategies to overcome this resistance. In this paper, a Chlorin-based photoactivable Galectin-3-inhibitor nanoliposome (PGIL) was designed for enhanced Melanoma PDT and immune activation of Natural Killer (NK) cells. PGIL were synthesized by encapsulating the photosensitizer chlorin e6 and low molecular citrus pectin in the nanoliposome to realize NIR-triggered PDT and low molecular citrus pectin (LCP) release into the cytoplasm. The intracellular release of LCP inhibits the activity of galectin-3, which increases the apoptosis, inhibits the invade ability, and enhances the recognition ability of Natural Killer (NK) cells to tumor cells in melanoma cells after PDT. These effects of PGIL were tested in cells and nude mice, and the mechanisms during the in vivo treatment were preliminarily studied. The results showed that PGIL can be an effective prodrug for melanoma therapy.

AB - Photodynamic therapy (PDT) is an encouraging alternative therapy for melanoma treatment and Ce6-mediated PDT has shown some exciting results in clinical trials. However, PDT in melanoma treatment is still hampered by some melanoma's protective mechanisms like antiapoptosis mechanisms and treatment escape pathways. Combined therapy and enhancing immune stimulation were proposed as effective strategies to overcome this resistance. In this paper, a Chlorin-based photoactivable Galectin-3-inhibitor nanoliposome (PGIL) was designed for enhanced Melanoma PDT and immune activation of Natural Killer (NK) cells. PGIL were synthesized by encapsulating the photosensitizer chlorin e6 and low molecular citrus pectin in the nanoliposome to realize NIR-triggered PDT and low molecular citrus pectin (LCP) release into the cytoplasm. The intracellular release of LCP inhibits the activity of galectin-3, which increases the apoptosis, inhibits the invade ability, and enhances the recognition ability of Natural Killer (NK) cells to tumor cells in melanoma cells after PDT. These effects of PGIL were tested in cells and nude mice, and the mechanisms during the in vivo treatment were preliminarily studied. The results showed that PGIL can be an effective prodrug for melanoma therapy.

UR - https://www.scopus.com/pages/publications/85074910288

U2 - 10.1021/acsami.9b09560

DO - 10.1021/acsami.9b09560

M3 - Journal articles

C2 - 31617343

AN - SCOPUS:85074910288

SN - 1944-8244

VL - 11

SP - 41829

EP - 41841

JO - ACS Applied Materials and Interfaces

JF - ACS Applied Materials and Interfaces

IS - 45

ER -

Chlorin-Based Photoactivable Galectin-3-Inhibitor Nanoliposome for Enhanced Photodynamic Therapy and NK Cell-Related Immunity in Melanoma

Abstract

Funding

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this